Valérie Soenen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Valérie Soenen has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Claude Preudhomme
Chru of Lille, Lille, France
19 shared publications - Bruno Quesnel
CHU Lille, UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, Lille, France
7 shared publications - Catherine Roche-Lestienne
Institut de Génétique Hôpital Jeanne de Flandre, CHU Lille Lille France
7 shared publications Christophe Roumier
Laboratory d’Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
7 shared publicationsA Cosson
5 shared publicationsAline Renneville
Laboratory d’Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
5 shared publications
Latest Publications
- 8 January 2018
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 78 (3) , 159-164
A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice
According to WHO recommendations, diagnosis of chronic myelomonocytic leukemia (CMML) beforehand requires microscopic examination of peripheral blood to identify dysplasia and/or blasts when monocytes are greater or equal to 1.0 × 109/L and 10% of leucocytes. We analyzed parameters derived from SysmexTM XN analyzers to improve the management of microscopic examination for monocytosis. We analyzed results of the complete blood count and the positioning and dispersion parameters of polymorphonuclear neutrophils and monocytes in 61 patients presenting with CMML and 635 control patients presenting with a reactive monocytosis. We used logistic regression and multivariate analysis to define a score for smear review. Three parameters were selected: neutrophil/monocyte ratio, structural neutrophil dispersion (Ne-WX) and monocyte absolute value. We established an equation in which the threshold of 0.160 guided microscopic examination in the search for CMML abnormalities with a sensitivity of 0.967 and a specificity of 0.978 in the learning cohort (696 samples) and 0.923 and 0.936 in the validation cohort (1809 samples) respectively. We created a score for microscopic smear examination of patients presenting with a monocytosis greater or equal to 1.0 × 109/L and 10% of leucocytes, improving efficiency in laboratory routine practice.
- 8 January 2018
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 78 (3) , 159-164
A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice
According to WHO recommendations, diagnosis of chronic myelomonocytic leukemia (CMML) beforehand requires microscopic examination of peripheral blood to identify dysplasia and/or blasts when monocytes are greater or equal to 1.0 × 109/L and 10% of leucocytes. We analyzed parameters derived from SysmexTM XN analyzers to improve the management of microscopic examination for monocytosis. We analyzed results of the complete blood count and the positioning and dispersion parameters of polymorphonuclear neutrophils and monocytes in 61 patients presenting with CMML and 635 control patients presenting with a reactive monocytosis. We used logistic regression and multivariate analysis to define a score for smear review. Three parameters were selected: neutrophil/monocyte ratio, structural neutrophil dispersion (Ne-WX) and monocyte absolute value. We established an equation in which the threshold of 0.160 guided microscopic examination in the search for CMML abnormalities with a sensitivity of 0.967 and a specificity of 0.978 in the learning cohort (696 samples) and 0.923 and 0.936 in the validation cohort (1809 samples) respectively. We created a score for microscopic smear examination of patients presenting with a monocytosis greater or equal to 1.0 × 109/L and 10% of leucocytes, improving efficiency in laboratory routine practice.
- Open Access
- 7 June 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (34) , 57451-57459
BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Charles Herbaux1, 2, Elisabeth Bertrand1, Guillemette Marot3, Christophe Roumier4, Nicolas Poret1, Valérie Soenen4, Olivier Nibourel4, Catherine Roche-Lestienne4, Natacha Broucqsault1, Sylvie Galiègue-Zouitina1, Eileen M Boyle2, Guillemette Fouquet2, Aline Renneville4, Sabine Tricot5, Franck Morschhauser2, Claude Preudhomme4, Bruno Quesnel1, 2, Stephanie Poulain5 and Xavier Leleu6, 7 1Inserm U837, Team 3, Cancer Research Institute of Lille, Lille, France 2Service des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France 3Lille Nord de France University, Equipe Biostatistique, UDSL, Lille, France 4Laboratory d’Hématologie, Biologie and Pathologie Center, CHRU, Lille, France 5Département d’Hématologie-Immunologie-Cytogénétique, CH, Valenciennes, France 6Service d’Hématolgie et Thérapie cellulaire, Hématologie, CHU, Poitiers, France 7Centre d’Investigation Clinique Inserm, CHU, Poitiers, France Correspondence to: Xavier Leleu, email: xavier.leleu@chu-poitiers.fr Keywords: BACH2, Waldenström macroglobulinemia, indolent, progression, physiopathology Received: February 21, 2016 Accepted: May 12, 2016 Published: June 07, 2016 ABSTRACT Approximately 30% of the patients who fulfil the criteria of Waldenström’s macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A- to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile, BACH2, a B-cell transcription factor known to be a tumor suppressor gene, was found to be over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in a WM-related cell line and observed a significant reduction of the clonogenic activity. To the best of our knowledge, we report for the first time a specific gene expression signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 was identified as a candidate gene that may help to understand better the behavior of tumor cells in indolent WM.
- 7 June 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (34) , 57451-57459
Open AccessBACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Charles Herbaux1, 2, Elisabeth Bertrand1, Guillemette Marot3, Christophe Roumier4, Nicolas Poret1, Valérie Soenen4, Olivier Nibourel4, Catherine Roche-Lestienne4, Natacha Broucqsault1, Sylvie Galiègue-Zouitina1, Eileen M Boyle2, Guillemette Fouquet2, Aline Renneville4, Sabine Tricot5, Franck Morschhauser2, Claude Preudhomme4, Bruno Quesnel1, 2, Stephanie Poulain5 and Xavier Leleu6, 7 1Inserm U837, Team 3, Cancer Research Institute of Lille, Lille, France 2Service des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France 3Lille Nord de France University, Equipe Biostatistique, UDSL, Lille, France 4Laboratory d’Hématologie, Biologie and Pathologie Center, CHRU, Lille, France 5Département d’Hématologie-Immunologie-Cytogénétique, CH, Valenciennes, France 6Service d’Hématolgie et Thérapie cellulaire, Hématologie, CHU, Poitiers, France 7Centre d’Investigation Clinique Inserm, CHU, Poitiers, France Correspondence to: Xavier Leleu, email: xavier.leleu@chu-poitiers.fr Keywords: BACH2, Waldenström macroglobulinemia, indolent, progression, physiopathology Received: February 21, 2016 Accepted: May 12, 2016 Published: June 07, 2016 ABSTRACT Approximately 30% of the patients who fulfil the criteria of Waldenström’s macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A- to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile, BACH2, a B-cell transcription factor known to be a tumor suppressor gene, was found to be over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in a WM-related cell line and observed a significant reduction of the clonogenic activity. To the best of our knowledge, we report for the first time a specific gene expression signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 was identified as a candidate gene that may help to understand better the behavior of tumor cells in indolent WM.
- Open Access
- 15 November 2013
- Published by American Society of Hematology in Blood
- Vol. 122 (21) , 2620
The B7-H3 Protein In Acute Myeloid Leukemia
The B7 family of costimulatory molecules comprises several members, such as PD-L1 (B7-H1), that may participate in the immunoescape of tumor cells. For instance, the expression of PD-L1 in cancer cells can induce immunotolerance by deactivating T cells in several hematological malignancies, including acute myeloid leukemia (AML) and MDS. The B7-H3 (B7-homolog 3 or CD276) is a type I transmembrane protein and a member of the B7 family. B7-H3 is expressed in many tissues and in antigen-presenting cells. Its functions and counter receptor(s) remain unclear. The expression of the B7-H3 protein by the tumor microenvironment and tumor cells modifies the antitumor immune reaction, tumor growth, metastatic ability and drug resistance. B7-H3 is widely expressed in solid cancers and seems to be a prognostic marker in several tumor types. Clinical grade anti-B7-H3 antibodies are under development. The role of B7-H3 and its expression in AML has not yet been well investigated. We examined the expression of B7-H3 in the blast cells of a cohort of patients with AML to determine whether its expression affected the patients’ prognoses. Our retrospective study included 111 patients (18 children and 93 adults) treated for AML between 2009 and 2011. We measured B7-H3 expression in bone marrow mononuclear cells using multiparameter flow cytometry (CD56, B7-H3, CD34, CD123, CD14, CD38 and CD45). We investigated the correlation of B7-H3 expression with biological, molecular and cytogenetic markers as well as the patient’s clinical characteristics. FLT3-ITD, NPM1 and CEBPA mutations were screened by the conventional Sanger methodology according to the ELN recommendations. B7-H3 expression was low and invariable in lymphocytes and high in monocytes. According to the MFI (Mean Fluorescence Intensity) ratio of blasts/lymphocytes, the B7-H3 expression level in blasts was widely variable (0.80 to 10.38). The threshold retained in our study was 3. Twenty seven percent (30/111) of AML samples were positive, and positive samples primarily included the M5 and M3 FAB subtypes (50% of B7-H3 positive patients). The expression of B7-H3 did not correlate with age (p=0.86), sex (p=0.79), leucocytosis (p=0.38) or NPM1 mutation status (p=0.08). The expression of B7-H3 was significantly higher in adverse karyotypes (pBerthon:CELGENE: Research Funding. Preudhomme:CELGENE: Research Funding.
- 15 November 2013
- Published by American Society of Hematology in Blood
- Vol. 122 (21) , 2620
Open AccessThe B7-H3 Protein In Acute Myeloid Leukemia
The B7 family of costimulatory molecules comprises several members, such as PD-L1 (B7-H1), that may participate in the immunoescape of tumor cells. For instance, the expression of PD-L1 in cancer cells can induce immunotolerance by deactivating T cells in several hematological malignancies, including acute myeloid leukemia (AML) and MDS. The B7-H3 (B7-homolog 3 or CD276) is a type I transmembrane protein and a member of the B7 family. B7-H3 is expressed in many tissues and in antigen-presenting cells. Its functions and counter receptor(s) remain unclear. The expression of the B7-H3 protein by the tumor microenvironment and tumor cells modifies the antitumor immune reaction, tumor growth, metastatic ability and drug resistance. B7-H3 is widely expressed in solid cancers and seems to be a prognostic marker in several tumor types. Clinical grade anti-B7-H3 antibodies are under development. The role of B7-H3 and its expression in AML has not yet been well investigated. We examined the expression of B7-H3 in the blast cells of a cohort of patients with AML to determine whether its expression affected the patients’ prognoses. Our retrospective study included 111 patients (18 children and 93 adults) treated for AML between 2009 and 2011. We measured B7-H3 expression in bone marrow mononuclear cells using multiparameter flow cytometry (CD56, B7-H3, CD34, CD123, CD14, CD38 and CD45). We investigated the correlation of B7-H3 expression with biological, molecular and cytogenetic markers as well as the patient’s clinical characteristics. FLT3-ITD, NPM1 and CEBPA mutations were screened by the conventional Sanger methodology according to the ELN recommendations. B7-H3 expression was low and invariable in lymphocytes and high in monocytes. According to the MFI (Mean Fluorescence Intensity) ratio of blasts/lymphocytes, the B7-H3 expression level in blasts was widely variable (0.80 to 10.38). The threshold retained in our study was 3. Twenty seven percent (30/111) of AML samples were positive, and positive samples primarily included the M5 and M3 FAB subtypes (50% of B7-H3 positive patients). The expression of B7-H3 did not correlate with age (p=0.86), sex (p=0.79), leucocytosis (p=0.38) or NPM1 mutation status (p=0.08). The expression of B7-H3 was significantly higher in adverse karyotypes (pBerthon:CELGENE: Research Funding. Preudhomme:CELGENE: Research Funding.
- Open Access
- 16 July 2013
- Published by Wiley in American Journal of Hematology
- Vol. 88 (11) , 948-954
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia
SNP array (SNPa) was developed to detect copy number alteration (CNA) and loss of heterozygosity (LOH) without copy number changes, CN‐LOH. We aimed to identify novel genomic aberrations using SNPa in 31 WM with paired samples. Methylation status and mutation were analyzed on target genes. A total of 61 genetic aberrations were observed, 58 CNA (33 gains, 25 losses) in 58% of patients and CN‐LOH in 6% of patients. The CNA were widely distributed throughout the genome, including 12 recurrent regions and identified new cryptic clonal chromosomal lesions that were mapped. Gene set expression analysis demonstrated a relationship between either deletion 6q or gain of chromosome 4 and alteration of gene expression profiling. We then studied methylation status and sought for mutations in altered regions on target genes. We observed methylation of DLEU7 on chromosome 13 in all patients (n = 12) with WM, and mutations of CD79B/CD79A genes (17q region), a key component of the BCR pathway, in 15% of cases. Most importantly, higher frequency of ≥3 CNA was observed in symptomatic WM. In conclusion, this study expands the view of the genomic complexity of WM, especially in symptomatic WM, including a potentially new mechanism of gene dysfunction, acquired uniparental disomy/CN‐LOH. Finally, we have identified new potential target genes in WM, such as DLEU7 and CD79A/B. Am. J. Heamtol. 88:948–954, 2013.
- 16 July 2013
- Published by Wiley in American Journal of Hematology
- Vol. 88 (11) , 948-954
Open AccessGenome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia
SNP array (SNPa) was developed to detect copy number alteration (CNA) and loss of heterozygosity (LOH) without copy number changes, CN‐LOH. We aimed to identify novel genomic aberrations using SNPa in 31 WM with paired samples. Methylation status and mutation were analyzed on target genes. A total of 61 genetic aberrations were observed, 58 CNA (33 gains, 25 losses) in 58% of patients and CN‐LOH in 6% of patients. The CNA were widely distributed throughout the genome, including 12 recurrent regions and identified new cryptic clonal chromosomal lesions that were mapped. Gene set expression analysis demonstrated a relationship between either deletion 6q or gain of chromosome 4 and alteration of gene expression profiling. We then studied methylation status and sought for mutations in altered regions on target genes. We observed methylation of DLEU7 on chromosome 13 in all patients (n = 12) with WM, and mutations of CD79B/CD79A genes (17q region), a key component of the BCR pathway, in 15% of cases. Most importantly, higher frequency of ≥3 CNA was observed in symptomatic WM. In conclusion, this study expands the view of the genomic complexity of WM, especially in symptomatic WM, including a potentially new mechanism of gene dysfunction, acquired uniparental disomy/CN‐LOH. Finally, we have identified new potential target genes in WM, such as DLEU7 and CD79A/B. Am. J. Heamtol. 88:948–954, 2013.
- Open Access
- 30 May 2013
- Published by American Society of Hematology in Blood
- Vol. 121 (22) , 4504-4511
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Mutation of the MYD88 gene has recently been identified in activated B-cell–like diffuse cell lymphoma and enhanced Janus kinase/signal transducer and activator of transcription (JAK-STAT) and nuclear factor κB (NF-κB) signaling pathways. A whole exome–sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high frequency of MYD88 L265P mutation in WM. The genetic background is not fully deciphered in WM, although the role of NF-κB and JAK-STAT has been demonstrated. We analyzed MYD88 mutation in exon 5 and characterized the clinical significance of this genetic alteration in 67 WM patients. Clinical features; immunophenotypic markers; and conventional cytogenetic, fluorescence in situ hybridization, and single nucleotide polymorphism array data were analyzed. MYD88 L265P mutation was acquired in 79% of patients. Overall, we have identified alteration of the MYD88 locus in 91% of WM patients, including 12% with gain on chromosome 3 at the 3p22 locus that included the MYD88 gene. Patients with absence of MYD88 mutation were WM characterized with a female predominance, a splenomegaly, gain of chromosome 3, and CD27 expression. Importantly, inhibition of MYD88 signaling induced cytotoxicity and inhibited cell growth of cell lines issued from patients with WM. In conclusion, these results confirm a high frequency of MYD88 L265P mutation in WM. The discovery of MYD88 L265P mutation may contribute to a better understanding of the physiopathogeny of WM.
- 30 May 2013
- Published by American Society of Hematology in Blood
- Vol. 121 (22) , 4504-4511
Open AccessMYD88 L265P mutation in Waldenstrom macroglobulinemia
Mutation of the MYD88 gene has recently been identified in activated B-cell–like diffuse cell lymphoma and enhanced Janus kinase/signal transducer and activator of transcription (JAK-STAT) and nuclear factor κB (NF-κB) signaling pathways. A whole exome–sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high frequency of MYD88 L265P mutation in WM. The genetic background is not fully deciphered in WM, although the role of NF-κB and JAK-STAT has been demonstrated. We analyzed MYD88 mutation in exon 5 and characterized the clinical significance of this genetic alteration in 67 WM patients. Clinical features; immunophenotypic markers; and conventional cytogenetic, fluorescence in situ hybridization, and single nucleotide polymorphism array data were analyzed. MYD88 L265P mutation was acquired in 79% of patients. Overall, we have identified alteration of the MYD88 locus in 91% of WM patients, including 12% with gain on chromosome 3 at the 3p22 locus that included the MYD88 gene. Patients with absence of MYD88 mutation were WM characterized with a female predominance, a splenomegaly, gain of chromosome 3, and CD27 expression. Importantly, inhibition of MYD88 signaling induced cytotoxicity and inhibited cell growth of cell lines issued from patients with WM. In conclusion, these results confirm a high frequency of MYD88 L265P mutation in WM. The discovery of MYD88 L265P mutation may contribute to a better understanding of the physiopathogeny of WM.
- Open Access
- 18 October 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (3) , 663-668
Construction of a tube-shaped tracheal substitute using fascial flap-wrapped revascularized allogenic aorta
Animal studies have demonstrated the feasibility of tracheal replacement by silicone-stented allogenic aortas (AAs), showing mature cartilage regeneration into the grafts. In clinical trials, this graft did not prove stiff enough to allow long-term stent withdrawal. This graft insufficiency could be due to ischaemic phase prior to neoangiogenesis. To solve this issue, we investigated both the efficacy of the rabbit lateral thoracic fascial flap as a vehicle for revascularization of the AA and construction of a tube-shaped graft with transferable vascular pedicle, for more efficient replacement of the trachea. Thirty-four New Zealand rabbits were used. After harvesting of donors ‘thoracic aortas’, the fresh aortic allografts were transplanted within 1 h, and the others were cryopreserved. Fifteen male and four female rabbits were used as recipients for fresh (n = 9) or cryopreserved (n = 10) aortic allografts that were implanted under the skin of the chest wall, after graft wrap using a pedicled lateral thoracic fascial flap. Animal sacrifice was scheduled at regular intervals up to 61 days. Macroscopic and microscopic examinations and fluorescence in situ hybridization (FISH) were used to study the morphology, revascularization process and viability of the construct. There was no operative death. Animals showed no graft rejection, despite the absence of immunosuppressive therapy. They all had a satisfactory tubular morphology of their construct. Of the 19 rabbits, 15 were found to have a generally preserved histological structure of the aorta and satisfactory neoangiogenesis. In the last four, a severe wound complication was associated with necrosis of the aortic graft. FISH on three aortic grafts with satisfactory neoangiogenesis showed migration of recipient cells into the aortic graft, decreasing from the adventitial to the luminal side, associated with the persistence of cells from the donor. Our results showed that the chimeric construct transformed into a well-vascularized tube-shaped organ with transferable pedicle and some degree of stiffness. Persistence of donor's cells of normal morphology into the aortic graft was suggestive of minimal ischaemia during the initial phase of revascularization. This construct might be investigated in the setting of tracheal replacement in the rabbit model.
- 18 October 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (3) , 663-668
Open AccessConstruction of a tube-shaped tracheal substitute using fascial flap-wrapped revascularized allogenic aorta
Animal studies have demonstrated the feasibility of tracheal replacement by silicone-stented allogenic aortas (AAs), showing mature cartilage regeneration into the grafts. In clinical trials, this graft did not prove stiff enough to allow long-term stent withdrawal. This graft insufficiency could be due to ischaemic phase prior to neoangiogenesis. To solve this issue, we investigated both the efficacy of the rabbit lateral thoracic fascial flap as a vehicle for revascularization of the AA and construction of a tube-shaped graft with transferable vascular pedicle, for more efficient replacement of the trachea. Thirty-four New Zealand rabbits were used. After harvesting of donors ‘thoracic aortas’, the fresh aortic allografts were transplanted within 1 h, and the others were cryopreserved. Fifteen male and four female rabbits were used as recipients for fresh (n = 9) or cryopreserved (n = 10) aortic allografts that were implanted under the skin of the chest wall, after graft wrap using a pedicled lateral thoracic fascial flap. Animal sacrifice was scheduled at regular intervals up to 61 days. Macroscopic and microscopic examinations and fluorescence in situ hybridization (FISH) were used to study the morphology, revascularization process and viability of the construct. There was no operative death. Animals showed no graft rejection, despite the absence of immunosuppressive therapy. They all had a satisfactory tubular morphology of their construct. Of the 19 rabbits, 15 were found to have a generally preserved histological structure of the aorta and satisfactory neoangiogenesis. In the last four, a severe wound complication was associated with necrosis of the aortic graft. FISH on three aortic grafts with satisfactory neoangiogenesis showed migration of recipient cells into the aortic graft, decreasing from the adventitial to the luminal side, associated with the persistence of cells from the donor. Our results showed that the chimeric construct transformed into a well-vascularized tube-shaped organ with transferable pedicle and some degree of stiffness. Persistence of donor's cells of normal morphology into the aortic graft was suggestive of minimal ischaemia during the initial phase of revascularization. This construct might be investigated in the setting of tracheal replacement in the rabbit model.
- 1 February 2011
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1) , 106-108
High-Throughput Genomic Analysis in Waldenström's Macroglobulinemia
- 1 February 2011
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1) , 106-108
High-Throughput Genomic Analysis in Waldenström's Macroglobulinemia
- 1 May 2010
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 31 (5) , 385-394
Macroglobulinémie de Waldenström
- 1 May 2010
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 31 (5) , 385-394
Macroglobulinémie de Waldenström
- 9 July 2008
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 47 (10) , 915-918
Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia
- 9 July 2008
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 47 (10) , 915-918
Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia